Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Evidence- |
RCV000225640 | SCV000282296 | pathogenic | Breast-ovarian cancer, familial 1 | 2016-04-22 | reviewed by expert panel | curation | Variant allele predicted to encode a truncated non-functional protein. |
Ambry Genetics | RCV000166800 | SCV000217614 | pathogenic | Hereditary cancer-predisposing syndrome | 2014-11-04 | criteria provided, single submitter | clinical testing | Lines of evidence used in support of classification: Alterations resulting in premature truncation (e.g.reading frame shift, nonsense) |
Consortium of Investigators of Modifiers of BRCA1/2 |
RCV000225640 | SCV000325509 | pathogenic | Breast-ovarian cancer, familial 1 | 2015-10-02 | criteria provided, single submitter | clinical testing | |
Gene |
RCV000487157 | SCV000567865 | pathogenic | not provided | 2016-08-09 | criteria provided, single submitter | clinical testing | This pathogenic variant is denoted BRCA1 c.2963C>A at the cDNA level and p.Ser988Ter (S988X) at the protein level. The substitution creates a nonsense variant, which changes a Serine to a premature stop codon (TCA>TAA), and is predicted to cause loss of normal protein function through either protein truncation or nonsense-mediated mRNA decay. This variant, previously published as 3082C>A using alternate nomenclature, has been observed in association with breast and ovarian cancer (Scott 2003, Alsop 2012, Konstantopoulou 2014). Based on the current evidence, we consider this variant to be pathogenic. |